0001493152-20-015009.txt : 20200810 0001493152-20-015009.hdr.sgml : 20200810 20200807204232 ACCESSION NUMBER: 0001493152-20-015009 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20200810 DATE AS OF CHANGE: 20200807 EFFECTIVENESS DATE: 20200810 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOTRICITY INC. CENTRAL INDEX KEY: 0001630113 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 472548273 STATE OF INCORPORATION: NV FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-372826 FILM NUMBER: 201086585 BUSINESS ADDRESS: STREET 1: 75 INTERNATIONAL BLVD., SUITE 300 CITY: TORONTO STATE: A6 ZIP: M9W 6L9 BUSINESS PHONE: (416) 214-3678 MAIL ADDRESS: STREET 1: 75 INTERNATIONAL BLVD., SUITE 300 CITY: TORONTO STATE: A6 ZIP: M9W 6L9 FORMER COMPANY: FORMER CONFORMED NAME: METASOLUTIONS, INC. DATE OF NAME CHANGE: 20150107 D 1 primary_doc.xml X0708 D LIVE 0001630113 BIOTRICITY INC. 275 SHORELINE DRIVE, SUITE 150 REDWOOD CITY CA CALIFORNIA 94065 650 832-1626 NEVADA Meta Solutions METASOLUTIONS, INC. Corporation true Waqaas Al-Siddiq 275 Shoreline Drive, Suite 150 Redwood City CA CALIFORNIA 94065 Executive Officer Director Norman Betts 275 Shoreline Drive, Suite 150 Redwood City CA CALIFORNIA 94065 Director Patricia Kennedy 275 Shoreline Drive, Suite 150 Redwood City CA CALIFORNIA 94065 Director David Rosa 275 Shoreline Drive, Suite 150 Redwood City CA CALIFORNIA 94065 Director Steve Salmon 275 Shoreline Drive, Suite 150 Redwood City CA CALIFORNIA 94065 Director John Ayanoglou 275 Shoreline Drive, Suite 150 Redwood City CA CALIFORNIA 94065 Executive Officer Biotechnology Decline to Disclose 06b false 2020-07-14 false true true true true false 100000 Paulson Investment Company 5670 None None 40 WALL STREET, 39TH FLOOR NEW YORK NY NEW YORK 10005 CA CALIFORNIA FL FLORIDA MD MARYLAND MI MICHIGAN MN MINNESOTA MT MONTANA NY NEW YORK OR OREGON PA PENNSYLVANIA TN TENNESSEE VA VIRGINIA WA WASHINGTON false 10000000 1253000 8747000 false 24 1200000 true 0 0 The Company will pay the placement agent a commission of 12% of the gross proceeds the Company receives in the offering from investors introduced to the Company by the placement agent and of 5% for any other investors. false BIOTRICITY INC. /s/ John Ayanoglou John Ayanoglou Chief Financial Officer 2020-08-07